Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : Arcutis Biotherapeutics
Deal Size : $40.0 million
Deal Type : Collaboration
Arcutis and Sato Announce Strategic Collaboration for Topical Roflumilast in Japan
Details : The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.
Brand Name : Zoryve
Molecule Type : Small molecule
Upfront Cash : $25.0 million
February 28, 2024
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Arcutis Biotherapeutics
Deal Size : $40.0 million
Deal Type : Collaboration
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : EPI Health
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...
Brand Name : Rhofade
Molecule Type : Small molecule
Upfront Cash : $5.0 million
December 21, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : EPI Health
Deal Size : $7.5 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
